Seeking Alpha
31 Oct 2026, 11:33 UTC · 1h ago
Aura Biosciences: A Pivotal Trial Engineered With Room To Spare
Impact · against what's priced in
AURA is a high-conviction binary play on 2027 Phase 3 data with a significant cash cushion. The current valuation is primarily driven by the balance sheet, leaving the late-stage bel-sar asset largely undervalued by the market.
- AURA+0.40
No priced-in read yet
- In context
The company's $323.8 million cash position secures operations into 1H 2029, removing dilution risk before the critical 2027 Phase 3 readout for bel-sar.
Read from the article alone
Search tags
